ArticleHead & neck2026
Characteristics and Outcome of Patients With Refractory Orbital Rhabdomyosarcoma.
Article in Head & neck, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundOrbital rhabdomyosarcoma (oRMS) is a rare pediatric soft-tissue sarcoma with generally excellent outcomes; however, a subset of patients relapse, and evidence on optimal salvage strategies and long-term survival after recurrence remains limited.
methodsPediatric patients with oRMS enrolled in the cooperative protocols RMS79, RMS88, RMS96, and RMS2005 between 1979 and 2016.
resultsAmong 117 enrolled patients, 30 relapsed, predominantly with local recurrence. Relapse was associated with age < 1 year, female sex, RMS88 protocol, incomplete initial surgery, and omission of radiotherapy. Salvage treatments included multi-agent chemotherapy, radiotherapy, and surgery, with orbit exenteration performed in a total of 13 cases. After a median follow-up of 12.7 years from relapse, 10-year OS and EFS were 56.0% and 43.3%, respectively.
conclusionsAlthough oRMS usually has an excellent prognosis, relapse remains challenging. Multidisciplinary salvage therapy can yield long-term survival in over half of relapsed patients. Better initial treatment selection is needed to reduce relapse and late toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.